Nano-Antibiotics (NNAB) 0.2500 $NNAB
NanoAntibiotics to Begin Trading on the OTC Markets
Marketwire - Wed May 07, 4:58AM CDT
NanoAntibiotics Inc. (OTCQB: NNAB) (the "Company"

, a development stage nano-biotechnology company focused on the discovery, development, and commercialization of new anti-infective drugs to meet the growing clinical need created by multi-drug resistant bacterial pathogens, is pleased to announce that it has been informed that trading of its stock is to begin on the OTC Markets.
NanoAntibiotics Provides Update on Its Novel Efflux Pump Inhibitor
Marketwire - Thu Mar 27, 9:00AM CDT
NanoAntibiotics (OTCBB: NNAB) (the "Company"

, a development stage nano-biotechnology company focused on the discovery, development, and commercialization of new anti-infective drugs to meet the growing clinical need created by multi-drug resistant bacterial pathogens, is pleased to report successful preliminary in vitro results on its novel efflux pump inhibitor.